Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 1
2017 1
2020 2
2021 2
2022 5
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Uterine carcinosarcoma vs endometrial serous and clear cell carcinoma: A systematic review and meta-analysis of survival.
Raffone A, Travaglino A, Raimondo D, Maletta M, De Vivo V, Visiello U, Casadio P, Seracchioli R, Zullo F, Insabato L, Mollo A. Raffone A, et al. Int J Gynaecol Obstet. 2022 Sep;158(3):520-527. doi: 10.1002/ijgo.14033. Epub 2021 Dec 11. Int J Gynaecol Obstet. 2022. PMID: 34797919 Free PMC article. Review.
BACKGROUND: It is unclear whether uterine carcinosarcoma (UCS) is more aggressive than endometrial serous carcinoma (SC) and clear cell carcinoma (CCC). ...
BACKGROUND: It is unclear whether uterine carcinosarcoma (UCS) is more aggressive than endometrial serous carcinoma (SC) and c …
Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
Galaal K, Godfrey K, Naik R, Kucukmetin A, Bryant A. Galaal K, et al. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD006812. doi: 10.1002/14651858.CD006812.pub2. Cochrane Database Syst Rev. 2011. PMID: 21249682 Free PMC article. Updated. Review.
SELECTION CRITERIA: Randomised controlled trials comparing adjuvant radiotherapy and/or chemotherapy in women with uterine carcinosarcoma. DATA COLLECTION AND ANALYSIS: We independently abstracted data and assessed risk of bias. ...In the primary treatment/ first li …
SELECTION CRITERIA: Randomised controlled trials comparing adjuvant radiotherapy and/or chemotherapy in women with uterine carcino …
Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
Galaal K, van der Heijden E, Godfrey K, Naik R, Kucukmetin A, Bryant A, Das N, Lopes AD. Galaal K, et al. Cochrane Database Syst Rev. 2013 Feb 28;2013(2):CD006812. doi: 10.1002/14651858.CD006812.pub3. Cochrane Database Syst Rev. 2013. PMID: 23450572 Free PMC article. Review.
BACKGROUND: Uterine carcinosarcomas are uncommon with about 35% not confined to the uterus at diagnosis. The survival of women with advanced uterine carcinosarcoma is poor with a pattern of failure indicating greater likelihood of upper abdominal and distant metasta …
BACKGROUND: Uterine carcinosarcomas are uncommon with about 35% not confined to the uterus at diagnosis. The survival of women with advanced …
Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives.
Vitale SG, Laganà AS, Capriglione S, Angioli R, La Rosa VL, Lopez S, Valenti G, Sapia F, Sarpietro G, Butticè S, Tuscano C, Fanale D, Tropea A, Rossetti D. Vitale SG, et al. Int J Mol Sci. 2017 May 20;18(5):1100. doi: 10.3390/ijms18051100. Int J Mol Sci. 2017. PMID: 28531111 Free PMC article. Review.
In this paper, we aimed to gather the available evidence on the latest therapies for the treatment of CS. We performed a systematic review using the terms "uterine carcinosarcoma", "uterine Malignant Mixed Mullerian Tumors", "target therapies", "angiogenesis therapy …
In this paper, we aimed to gather the available evidence on the latest therapies for the treatment of CS. We performed a systematic review u …
Prognostic value of the TCGA molecular classification in uterine carcinosarcoma.
Travaglino A, Raffone A, Raimondo D, Arciuolo D, Angelico G, Valente M, Scaglione G, D'alessandris N, Casadio P, Inzani F, Mollo A, Santoro A, Seracchioli R, Franco Zannoni G. Travaglino A, et al. Int J Gynaecol Obstet. 2022 Jul;158(1):13-20. doi: 10.1002/ijgo.13937. Epub 2021 Oct 11. Int J Gynaecol Obstet. 2022. PMID: 34536971 Free PMC article. Review.
BACKGROUND: The TCGA molecular groups of endometrial carcinoma are "POLE-mutated" (POLEmut), "microsatellite-instable/mismatch repair-deficient" (MSI/MMRd), "TP53-mutated/p53-abnormal" (TP53mut/p53abn), and "no specific molecular profile" (NSMP). OBJECTIVE: Prognostic assessment …
BACKGROUND: The TCGA molecular groups of endometrial carcinoma are "POLE-mutated" (POLEmut), "microsatellite-instable/mismatch repair-defici …
Prognostic significance of heterologous component in carcinosarcoma of the gynecologic organs: a systematic review and meta-analysis.
Kim Y, Kang GH, Kim H. Kim Y, et al. J Gynecol Oncol. 2023 Nov;34(6):e73. doi: 10.3802/jgo.2023.34.e73. Epub 2023 Jun 26. J Gynecol Oncol. 2023. PMID: 37417301 Free PMC article.
Studies that evaluated survival effect of sarcomatous component based on histology in human ovarian or uterine carcinosarcoma were included. Two authors independently reviewed the references based on eligibility criteria and extracted the data including primary tumo …
Studies that evaluated survival effect of sarcomatous component based on histology in human ovarian or uterine carcinosarcoma …
The role of multimodal adjuvant therapy for FIGO I-II carcinosarcoma of the uterus: a systematic review.
van der Horst RL, van der Hel O, Lutgens L, van der Aa M, Slangen B, Kruitwagen R, Lalisang RI. van der Horst RL, et al. Crit Rev Oncol Hematol. 2022 Jul;175:103701. doi: 10.1016/j.critrevonc.2022.103701. Epub 2022 May 6. Crit Rev Oncol Hematol. 2022. PMID: 35533817 Free article. Review.
The uterine carcinosarcoma (UCS) is a rare entity with poor prognosis. ...
The uterine carcinosarcoma (UCS) is a rare entity with poor prognosis. ...
Minimally Invasive Compared With Open Surgery in High-Risk Endometrial Cancer: A Systematic Review and Meta-analysis.
Dinoi G, Ghoniem K, Murad MH, Segarra-Vidal B, Zanfagnin V, Coronado PJ, Kyrgiou M, Perrone AM, Zola P, Weaver A, McGree M, Fanfani F, Scambia G, Ramirez PT, Mariani A. Dinoi G, et al. Obstet Gynecol. 2023 Jan 1;141(1):59-68. doi: 10.1097/AOG.0000000000004995. Epub 2022 Nov 30. Obstet Gynecol. 2023. PMID: 36701610
Articles were included if reporting original data on overall survival and disease-free survival among patients with high-risk endometrial cancer, defined as International Federation of Gynecology and Obstetrics grade 3 endometrioid, serous, clear cell, mixed histology, or uter …
Articles were included if reporting original data on overall survival and disease-free survival among patients with high-risk endometrial ca …
Cancer risks associated with the germline MITF(E318K) variant.
Guhan SM, Artomov M, McCormick S, Njauw C-, Stratigos AJ, Shannon K, Ellisen LW, Tsao H. Guhan SM, et al. Sci Rep. 2020 Oct 13;10(1):17051. doi: 10.1038/s41598-020-74237-z. Sci Rep. 2020. PMID: 33051548 Free PMC article.
We found minimal evidence of MITF(E318K)'s contribution to non-melanoma cancer risk among individuals with low inherited risks of melanoma (OR 1.168; 95% CI 0.78-1.74; p = 0.454), suggesting that earlier reports of an association between this variant and other malignancies may be …
We found minimal evidence of MITF(E318K)'s contribution to non-melanoma cancer risk among individuals with low inherited risks of melanoma ( …
11 results